Depth and Durability of Response in Multiple Myeloma

Dr. Saad Usmani and Dr. Shaji Kumar examine the CEPHEUS findings on response depth and durability in newly diagnosed multiple myeloma, with particular emphasis on MRD negativity and its potential implications for treatment duration. Dr. Usmani reviews the higher rates of MRD negativity with D-VRd compared with VRd at the 10⁻⁵ and 10⁻⁶ thresholds and highlights the sustained MRD negativity observed at 12, 24, and 36 months. Dr. Kumar discusses how the greater difference in MRD negativity compared with conventional complete response rates illustrates the value of MRD as a measure for distinguishing treatment efficacy in contemporary multiple myeloma trials. The conversation then shifts to whether sustained MRD negativity could eventually help determine when treatment can be discontinued, particularly as deeper and more durable responses become achievable with modern regimens. Dr. Kumar references the Endurance study and ongoing response-guided treatment strategies while noting that prospective evidence is still needed to establish when therapy can safely be stopped. Dr. Usmani emphasizes that sustained MRD negativity may become an important factor in future treatment-duration studies.